Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single Dose, Open-label Study to Investigate the Pharmacokinetics and Safety of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function

Next Previous
X
Search
Trial Profile

A Phase 1, Single Dose, Open-label Study to Investigate the Pharmacokinetics and Safety of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iptacopan (Primary)
  • Indications Age-related macular degeneration; Atypical Haemolytic Uraemic Syndrome; Autoimmune disorders; IgA nephropathy; Lupus nephritis; Membranoproliferative glomerulonephritis; Membranous glomerulonephritis; Paroxysmal nocturnal haemoglobinuria; Thrombotic thrombocytopenic purpura
  • Focus Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 19 Jul 2022 Status changed from recruiting to completed.
    • 14 Dec 2021 Status changed from not yet recruiting to recruiting.
    • 18 Oct 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top